-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明，无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Forma Therapeutics (NASDAQ:FMTX) Sees Unusually-High Trading Volume
Forma Therapeutics (NASDAQ:FMTX) Sees Unusually-High Trading Volume
Shares of Forma Therapeutics Holdings, Inc. (NASDAQ:FMTX – Get Rating) saw strong trading volume on Friday . 36,469 shares changed hands during trading, a decline of 95% from the previous session's volume of 788,493 shares.The stock last traded at $20.00 and had previously closed at $20.24.
Wall Street Analysts Forecast Growth
Several equities analysts recently weighed in on the stock. HC Wainwright lowered shares of Forma Therapeutics from a "buy" rating to a "neutral" rating and cut their price objective for the company from $53.00 to $20.00 in a research report on Friday. SVB Leerink cut their price objective on shares of Forma Therapeutics from $25.00 to $23.00 and set an "outperform" rating on the stock in a research report on Friday, May 27th. Cantor Fitzgerald lowered shares of Forma Therapeutics from an "overweight" rating to a "neutral" rating in a research report on Thursday. Credit Suisse Group lowered shares of Forma Therapeutics from an "outperform" rating to a "neutral" rating and set a $20.00 price objective on the stock. in a research report on Friday. Finally, Jefferies Financial Group downgraded Forma Therapeutics from a "buy" rating to a "hold" rating and lowered their price target for the company from $28.00 to $20.00 in a report on Friday. Five analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Hold" and an average target price of $29.17.
Get Forma Therapeutics alerts:Forma Therapeutics Price Performance
The firm has a fifty day simple moving average of $9.50 and a 200 day simple moving average of $8.52. The company has a market cap of $956.10 million, a price-to-earnings ratio of -5.00 and a beta of 0.24.
Institutional Investors Weigh In On Forma Therapeutics
Several hedge funds and other institutional investors have recently modified their holdings of FMTX. Quantbot Technologies LP grew its stake in shares of Forma Therapeutics by 125.0% in the first quarter. Quantbot Technologies LP now owns 3,600 shares of the company's stock worth $33,000 after acquiring an additional 2,000 shares during the last quarter. Advisor Group Holdings Inc. grew its stake in shares of Forma Therapeutics by 17,885.7% in the first quarter. Advisor Group Holdings Inc. now owns 2,518 shares of the company's stock worth $33,000 after acquiring an additional 2,504 shares during the last quarter. Amalgamated Bank acquired a new stake in shares of Forma Therapeutics in the first quarter worth $38,000. US Bancorp DE grew its stake in shares of Forma Therapeutics by 282.5% in the first quarter. US Bancorp DE now owns 4,341 shares of the company's stock worth $40,000 after acquiring an additional 3,206 shares during the last quarter. Finally, Legal & General Group Plc grew its stake in shares of Forma Therapeutics by 56.3% in the second quarter. Legal & General Group Plc now owns 10,187 shares of the company's stock worth $70,000 after acquiring an additional 3,670 shares during the last quarter. Institutional investors and hedge funds own 87.39% of the company's stock.About Forma Therapeutics
(Get Rating)
Forma Therapeutics Holdings, Inc, a clinical-stage biopharmaceutical company, focuses on development and commercialization of novel therapeutics for treatment of rare hematologic diseases and cancers. Its core product candidates for development include FT-4202, which is Phase 1 trial for the treatment of sickle cell disease and other hemoglobinopathies; and FT-7051 for the treatment of metastatic castration-resistant prostate cancer.
Featured Stories
- Get a free copy of the StockNews.com research report on Forma Therapeutics (FMTX)
- Could Snap Stock Rebound As Management Restructures?
- MarketBeat: Week in Review 8/29 – 9/2
- Hormel Looks Cheap At These Levels
- Lululemon Set To Soar Into September
- Could Nike Stock be Oversold, but Still Overvalued?
Receive News & Ratings for Forma Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Forma Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
Shares of Forma Therapeutics Holdings, Inc. (NASDAQ:FMTX – Get Rating) saw strong trading volume on Friday . 36,469 shares changed hands during trading, a decline of 95% from the previous session's volume of 788,493 shares.The stock last traded at $20.00 and had previously closed at $20.24.
周五，Forma治疗控股公司(纳斯达克代码：FMTX-GET评级)的股票成交量强劲。36,469股股票在交易中易手，较前一交易日的788,493股下跌了95%。该股最新报20.00美元，此前收盘报20.24美元。
Wall Street Analysts Forecast Growth
华尔街分析师预测经济增长
Several equities analysts recently weighed in on the stock. HC Wainwright lowered shares of Forma Therapeutics from a "buy" rating to a "neutral" rating and cut their price objective for the company from $53.00 to $20.00 in a research report on Friday. SVB Leerink cut their price objective on shares of Forma Therapeutics from $25.00 to $23.00 and set an "outperform" rating on the stock in a research report on Friday, May 27th. Cantor Fitzgerald lowered shares of Forma Therapeutics from an "overweight" rating to a "neutral" rating in a research report on Thursday. Credit Suisse Group lowered shares of Forma Therapeutics from an "outperform" rating to a "neutral" rating and set a $20.00 price objective on the stock. in a research report on Friday. Finally, Jefferies Financial Group downgraded Forma Therapeutics from a "buy" rating to a "hold" rating and lowered their price target for the company from $28.00 to $20.00 in a report on Friday. Five analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Hold" and an average target price of $29.17.
几位股票分析师最近对该股进行了加码。在周五的一份研究报告中，HC Wainwright将Forma治疗公司的股票评级从“买入”下调至“中性”，并将该公司的目标价从53.00美元下调至20.00美元。SVB Leerink在5月27日星期五的一份研究报告中将Forma Treateutics的股票目标价从25.00美元下调至23.00美元，并对该股设定了“跑赢大盘”的评级。在周四的一份研究报告中，坎托·菲茨杰拉德将Forma治疗公司的股票评级从“增持”下调至“中性”。瑞士信贷集团将Forma Treateutics的股票评级从“跑赢大盘”下调至“中性”，并为该股设定了20.00美元的目标价。在周五的一份研究报告中。最后，杰富瑞金融集团在周五的一份报告中将Forma治疗公司的评级从“买入”下调至“持有”，并将该公司的目标价从28.00美元下调至20.00美元。五位分析师对该股的评级为持有，一位分析师对该股的评级为买入。根据MarketBeat的数据，该股目前的平均评级为持有，平均目标价为29.17美元。
Forma Therapeutics Price Performance
Forma治疗公司的价格表现
The firm has a fifty day simple moving average of $9.50 and a 200 day simple moving average of $8.52. The company has a market cap of $956.10 million, a price-to-earnings ratio of -5.00 and a beta of 0.24.
该公司的50日简单移动均线为9.50美元，200日简单移动均线为8.52美元。该公司市值为9.561亿美元，市盈率为-5.00倍，贝塔系数为0.24。
Institutional Investors Weigh In On Forma Therapeutics
机构投资者对Forma Treeutics的看法
About Forma Therapeutics
关于Forma Treateutics
(Get Rating)
(获取评级)
Forma Therapeutics Holdings, Inc, a clinical-stage biopharmaceutical company, focuses on development and commercialization of novel therapeutics for treatment of rare hematologic diseases and cancers. Its core product candidates for development include FT-4202, which is Phase 1 trial for the treatment of sickle cell disease and other hemoglobinopathies; and FT-7051 for the treatment of metastatic castration-resistant prostate cancer.
Forma治疗控股公司是一家临床阶段的生物制药公司，专注于治疗罕见血液疾病和癌症的新疗法的开发和商业化。其待开发的核心产品包括FT-4202，这是治疗镰状细胞疾病和其他血红蛋白疾病的第一阶段试验；以及FT-7051，用于治疗转移性去势抵抗前列腺癌。
Featured Stories
专题报道
- Get a free copy of the StockNews.com research report on Forma Therapeutics (FMTX)
- Could Snap Stock Rebound As Management Restructures?
- MarketBeat: Week in Review 8/29 – 9/2
- Hormel Looks Cheap At These Levels
- Lululemon Set To Soar Into September
- Could Nike Stock be Oversold, but Still Overvalued?
- 免费获取StockNews.com关于Forma治疗(FMTX)的研究报告
- 随着管理层重组，股市能否迅速反弹？
- MarketBeat：回顾中的一周8/29-9/2
- 霍梅尔在这些水平上看起来很便宜
- 露露柠檬将飙升至9月
- 耐克股票会被超卖，但仍被高估吗？
Receive News & Ratings for Forma Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Forma Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受Forma治疗日报的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Forma Treateutics和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧